Latest news with #RECELL
Business Wire
7 hours ago
- Business
- Business Wire
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AVITA Medical, Inc. ('Avita' or the 'Company') (NASDAQ: RCEL) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVITA MEDICAL, INC. (RCEL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On August 7, 2025, Avita released its second quarter 2025 financial results, revealing 'a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.' The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company's wound care product, Recell, 'neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.' As a result, 'claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for RECELL procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in RECELL utilization during the first half of the year.' On this news, Avita's stock price fell $1.13, or 21%, to close at $4.25 per share on August 8, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Avita should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
10 hours ago
- Business
- Business Wire
AVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AVITA Medical, Inc. ('Avita' or the 'Company') (NASDAQ: RCEL) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AVITA MEDICAL, INC. (RCEL), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On August 7, 2025, Avita released its second quarter 2025 financial results, revealing 'a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.' The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company's wound care product, Recell, 'neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.' As a result, 'claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for RECELL procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in RECELL utilization during the first half of the year.' On this news, Avita's stock price fell $1.13, or 21%, to close at $4.25 per share on August 8, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Avita securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
a day ago
- Business
- Business Wire
Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of AVITA Medical, Inc. ('Avita' or the 'Company') (NASDAQ: RCEL) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON AVITA MEDICAL, INC. (RCEL), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On August 7, 2025, Avita released its second quarter 2025 financial results, revealing 'a six-month backlog in unpaid provider claims for Recell procedures impacted first-half demand.' The Company explained that contractors assigned by the Centers for Medicare & Medicaid Services to determine pricing of the Company's wound care product, Recell, 'neither assigned a price or assigned an inadequate price and failed to adjudicate claims in a timely manner.' As a result, 'claims accumulated from January through June, creating a significant backlog of unpaid claims and inadequately paid claims to providers for RECELL procedures. This lack of resolution created uncertainty among providers regarding payment expectations and timelines, which led to a reduction in RECELL utilization during the first half of the year.' On this news, Avita's stock price fell $1.13, or 21%, to close at $4.25 per share on August 8, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Avita securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Yahoo
28-07-2025
- Business
- Yahoo
AVITA Medical to Announce Second Quarter 2025 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, July 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2025 financial results after the close of the U.S. financial markets on Thursday, August 7, 2025. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 8, 2025, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights. The live webcast will be accessible under the Events & Presentations section of the AVITA Medical website at To participate by telephone, please register in advance to receive dial-in details and a personal PIN using the following link: A replay of the webcast will be available shortly after the live event on the Investor Relations website. About AVITA Medical, Inc. AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL® System, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications including burns and full-thickness skin defects. The RECELL System, excluding RECELL GO®, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit Investor & Media Contact:Ben AtkinsPhone +1-805 341 1571investor@ Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
Yahoo
04-06-2025
- Business
- Yahoo
AVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough Awards
VALENCIA, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering a portfolio of transformative solutions, today announced that RECELLⓇ, including RECELLⓇ GO, has been recognized as the 'Best New Technology Solution – Surgical' in the 2025 MedTech Breakthrough Awards. RECELL, FDA-approved for thermal burn wounds and full-thickness skin defects, has treated over 30,000 patients worldwide. RECELL requires significantly less donor skin than traditional grafting, reducing donor-site pain and accelerating recovery. Additional clinical outcomes include fewer procedures, improved functional and aesthetic results, and shorter hospital stays. RECELL GO retains these clinical benefits while enhancing procedural consistency and surgical team coordination, with the physician remaining central throughout the procedure. This design supports adoption in high-volume burn and trauma centers, and enables scalable, cost-efficient deployment across acute wound care settings. 'We appreciate this recognition, which highlights RECELL's advantages in burn and trauma care,' said Jim Corbett, Chief Executive Officer of AVITA Medical. 'By requiring significantly less donor skin than traditional grafting, RECELL reduces donor-site pain, accelerates healing and improves patient outcomes. We remain committed to expanding access and advancing care for patients.' The MedTech Breakthrough Awards honor companies and products shaping healthcare's future. The 2025 program drew over 4,500 nominations globally. In addition to this recognition, Dr. Katie Bush, Senior Vice President of Scientific & Medical Affairs of AVITA Medical, was awarded the 2025 Emerald Pinnacle Healthcare Award in the Medical Device category. The Pinnacle Award celebrates companies and individuals who have demonstrated exceptional innovation, leadership, and impact in healthcare. About AVITA Medical, Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL System®, approved by the FDA for the treatment of thermal burn wounds and full-thickness skin defects. RECELL harnesses the healing properties of a patient's own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point of care. In the U.S., AVITA Medical also holds the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix. In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including burns, full-thickness skin defects, and vitiligo. The RECELL System, excluding RECELL GO™, is TGA-registered in Australia, has received CE mark approval in Europe, and has PMDA approval in Japan. To learn more, visit Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements generally may be identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'forecast,' 'future,' 'goal,' 'guidance,' 'intend,' 'look forward,' 'may,' 'outlook,' 'project,' 'target,' 'will,' 'would,' and similar words or expressions, and the use of future dates. Forward-looking statements include, but are not limited to, statements relating to the timing and realization of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, as well as other economic or political conditions outside of the Company's control. These statements are made as of the date of this release, and the Company undertakes no obligation to publicly update or revise any of these statements, except as required by law. For additional information and other important factors that may cause actual results to differ materially from forward-looking statements, please see the 'Risk Factors' section of the Company's latest Annual Report on Form 10-K and other publicly available filings for a discussion of these and other risks and uncertainties. Authorized for release by the Chief Financial Officer of AVITA Medical, Inc. CONTACT: Investor & Media Contact: Jessica Ekeberg investor@ media@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
